SEC Company Response from NUCRYST Pharmaceuticals Corp. (CIK 0001344674) — Dec 21, 2005
NUCRYST Pharmaceuticals Corp. (CIK 0001344674)
Date: Dec. 21, 2005 · CIK: 0001344674 · Accession: 0000950137-05-015148
AI Filing Summary & Sentiment
File numbers found in text: 333-130073
Referenced dates: December 15, 2005
Letter
Re:
December 21, 2005
BY EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Sonia Barros
NUCRYST Pharmaceuticals Corp.
Registration Statement on Form F-1 (No. 333-130073)
Ladies and Gentlemen:
NUCRYST Pharmaceuticals Corp. (the “ Company”), in accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, hereby requests that the effectiveness of the above-referenced Registration Statement on Form F-1 be accelerated so that it will become effective at 5:00 p.m. (EST) on December 21, 2005, or as soon thereafter as practicable.
The Company hereby acknowledges that:
Ÿ
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
Ÿ
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
Ÿ
the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
NUCRYST PHARMACEUTICALS CORP.
By: /s/ ELIOT M. LURIER
Eliot M. Lurier
Vice President, Finance and Administration
December 21, 2005
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
NUCRYST Pharmaceuticals Inc.
Registration Statement on Form F-1
File No. 333-130073
Ladies and Gentlemen:
In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, we hereby join in the request of NUCRYST Pharmaceuticals Inc. (the “Company”) for acceleration of the effective date of the above-referenced registration statement relating to the Company’s offering of its common shares so that such registration statement is declared effective at 5:00 p.m. (Washington, D.C. time), or as soon as practicable thereafter, on December 21, 2005.
As we previously advised you in our letter dated December 15, 2005, the preliminary prospectus dated December 2, 2005 prepared by the Company in connection with the offering referred to above was distributed as follows:
3,600 copies
to
Underwriters (includes 4 underwriters and their respective sales force representatives)
1,700 copies
to
Institutions
50 copies
to
Others
Total:
5,350 copies
Sincerely yours,
JEFFERIES & COMPANY, INC.
Show Raw Text
CORRESP
1
filename1.htm
corresp
December 21, 2005
BY EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Sonia Barros
Re:
NUCRYST Pharmaceuticals Corp.
Registration Statement on Form F-1 (No. 333-130073)
Ladies and Gentlemen:
NUCRYST Pharmaceuticals Corp. (the “
Company”), in accordance with Rule 461 of the General
Rules and Regulations under the Securities Act of 1933, as amended, hereby requests that the
effectiveness of the above-referenced Registration Statement on Form F-1 be accelerated so that it
will become effective at 5:00 p.m. (EST) on December 21, 2005, or as soon thereafter as
practicable.
The Company hereby acknowledges that:
Ÿ
should the Commission or the staff, acting pursuant to delegated authority,
declare the filing effective, it does not foreclose the Commission from taking any
action with respect to the filing;
Ÿ
the action of the Commission or the staff, acting pursuant to delegated
authority, in declaring the filing effective, does not relieve the Company from its
full responsibility for the adequacy and accuracy of the disclosure in the filing; and
Ÿ
the Company may not assert this action as a defense in any proceeding initiated
by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
NUCRYST PHARMACEUTICALS CORP.
By:
/s/ ELIOT M. LURIER
Eliot M. Lurier
Vice President, Finance and Administration
December 21, 2005
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:
NUCRYST Pharmaceuticals Inc.
Registration Statement on Form F-1
File No. 333-130073
Ladies and Gentlemen:
In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of
1933, we hereby join in the request of NUCRYST Pharmaceuticals Inc. (the “Company”) for
acceleration of the effective date of the above-referenced registration statement relating to the
Company’s offering of its common shares so that such registration statement is declared effective
at 5:00 p.m. (Washington, D.C. time), or as soon as practicable
thereafter, on December 21, 2005.
As
we previously advised you in our letter dated December 15, 2005,
the preliminary prospectus dated December 2, 2005 prepared by
the Company in connection with the offering referred to above was
distributed as follows:
3,600 copies
to
Underwriters (includes 4 underwriters and their respective sales force representatives)
1,700 copies
to
Institutions
50 copies
to
Others
Total:
5,350 copies
Sincerely yours,
JEFFERIES & COMPANY, INC.
By:
/s/
Clifford Cohn
Authorized Signatory
As Representative of the several Underwriters